Comparative Pharmacology
Head-to-head clinical analysis: ASCLERA versus FILSPARI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASCLERA versus FILSPARI.
ASCLERA vs FILSPARI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ASCLERA (corticotropin) is a proopiomelanocortin (POMC) analog that stimulates the adrenal cortex to release cortisol, corticosterone, and aldosterone, increasing corticosteroid levels. It also has immunomodulatory and anti-inflammatory effects mediated through melanocortin receptors.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
Adults: 240 mg/m2 intravenously over 2 hours on day 1 of each 21-day cycle.
200 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours. In patients with moderate-to-severe renal impairment (CrCl < 30 mL/min), half-life may increase to 30-40 hours, requiring dose adjustment.
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
Renal excretion of unchanged drug accounts for 60-70% of administered dose; fecal/biliary elimination contributes 20-30%.
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Category C
Category C
Endothelin Receptor Antagonist
Endothelin Receptor Antagonist / ARB